Conservest Capital Advisors Inc. Makes New $91,000 Investment in COMPASS Pathways plc (NASDAQ:CMPS)

Conservest Capital Advisors Inc. bought a new position in shares of COMPASS Pathways plc (NASDAQ:CMPS) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 10,363 shares of the company’s stock, valued at approximately $91,000.

Other hedge funds have also modified their holdings of the company. Bailard Inc. purchased a new stake in shares of COMPASS Pathways during the 3rd quarter worth about $88,000. TAP Consulting LLC boosted its stake in shares of COMPASS Pathways by 14.7% during the 3rd quarter. TAP Consulting LLC now owns 12,845 shares of the company’s stock worth $95,000 after acquiring an additional 1,645 shares in the last quarter. AE Wealth Management LLC purchased a new stake in shares of COMPASS Pathways during the 3rd quarter worth about $106,000. Raymond James & Associates purchased a new stake in shares of COMPASS Pathways during the 3rd quarter worth about $205,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of COMPASS Pathways during the 3rd quarter worth about $597,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on CMPS shares. Morgan Stanley started coverage on shares of COMPASS Pathways in a research note on Monday, April 1st. They set an “overweight” rating and a $30.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 price target on shares of COMPASS Pathways in a research note on Friday, March 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a research note on Thursday, April 18th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $47.40.

COMPASS Pathways Price Performance

COMPASS Pathways stock traded up $0.08 during midday trading on Friday, reaching $7.94. The company had a trading volume of 258,441 shares, compared to its average volume of 574,167. The company has a market capitalization of $491.80 million, a P/E ratio of -3.32 and a beta of 2.48. COMPASS Pathways plc has a 12-month low of $5.01 and a 12-month high of $12.75. The firm’s fifty day simple moving average is $9.68 and its 200-day simple moving average is $8.41. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.33 and a quick ratio of 13.33.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). As a group, equities analysts anticipate that COMPASS Pathways plc will post -2.4 EPS for the current year.

Insider Buying and Selling at COMPASS Pathways

In other COMPASS Pathways news, major shareholder Ekaterina Malievskaia sold 25,750 shares of the stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $8.65, for a total value of $222,737.50. Following the completion of the sale, the insider now owns 4,036,154 shares in the company, valued at approximately $34,912,732.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other COMPASS Pathways news, major shareholder Ekaterina Malievskaia sold 25,750 shares of the stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $8.65, for a total value of $222,737.50. Following the completion of the sale, the insider now owns 4,036,154 shares in the company, valued at approximately $34,912,732.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director George Jay Goldsmith sold 15,740 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $10.58, for a total transaction of $166,529.20. Following the sale, the director now owns 4,079,107 shares of the company’s stock, valued at approximately $43,156,952.06. The disclosure for this sale can be found here. In the last quarter, insiders sold 140,601 shares of company stock worth $1,338,911. Insiders own 4.25% of the company’s stock.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.